Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Name: Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
Published: 2007
License: Public Domain

Genzyme, a Sanofi Company · 2007

ClinicalTrials.gov · Datasets · License: Public Domain · 2007

Open Source ↗

focal segmental glomerulosclerosis, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Related documents